{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:12:06Z","timestamp":1770333126179,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.vaccine.2006.07.056","type":"journal-article","created":{"date-parts":[[2006,8,18]],"date-time":"2006-08-18T11:13:23Z","timestamp":1155899603000},"page":"526-534","source":"Crossref","is-referenced-by-count":41,"title":["Increased potency of BioThrax\u00ae anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109"],"prefix":"10.1016","volume":"25","author":[{"given":"Mili","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Hine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"James Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lallan","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary S.","family":"Nabors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.07.056_bib1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2105\/AJPH.52.4.632","article-title":"Field evaluation of a human anthrax vaccine","volume":"52","author":"Brachman","year":"1962","journal-title":"Am J Pub Health"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2006.07.056_bib2","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1016\/S0264-410X(01)00021-4","article-title":"Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin","volume":"19","author":"Fellows","year":"2001","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2006.07.056_bib3","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2006.07.056_bib4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2672.1999.00897.x","article-title":"In vitro correlate of immunity in an animal model of inhalational anthrax","volume":"87","author":"Pitt","year":"1999","journal-title":"J Appl Microbiol"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2006.07.056_bib5","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(98)80112-6","article-title":"Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques","volume":"16","author":"Ivins","year":"1998","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2006.07.056_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nri1329","article-title":"Immunotherapeutic uses of CpG oligodeoxynucleotides","volume":"4","author":"Klinman","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.07.056_bib7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/eji.200324032","article-title":"Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities","volume":"34","author":"Vollmer","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2006.07.056_bib8","unstructured":"Rynkiewicz D, Rathkopf M, Ransom J, Sim I, Giri L, Quinn J, Waytes T, Al-Adhami M, Johnson W, Nielsen C. Marked enhancement of antibody responses in BioThrax anthrax vaccine with CPG7909 in healthy adult volunteers. Abstract LB-25, 45th ICAAC meeting, Washington, DC, December 16\u201319, 2005."},{"key":"10.1016\/j.vaccine.2006.07.056_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/108729001300338654","article-title":"Best minimally modified antisense oligonucleotides according to cell nuclease activity","volume":"11","author":"Samani","year":"2001","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/j.vaccine.2006.07.056_bib10","unstructured":"Anthrax Vaccine Adsorbed. United States Pharmacopeia. 27 ed. Rockville, MD, USP, 2004:p. 3042\u20134."},{"issue":"3","key":"10.1016\/j.vaccine.2006.07.056_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/prep.2000.1208","article-title":"Optimized production and purification of Bacillus anthracis lethal factor","volume":"18","author":"Park","year":"2000","journal-title":"Protein Expr Purif"},{"issue":"4804","key":"10.1016\/j.vaccine.2006.07.056_bib12","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1126\/science.3107127","article-title":"Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production","volume":"236","author":"Snapper","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2006.07.056_bib13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2006.07.056_bib14","unstructured":"The Anthrax Vaccine: is it Safe? Does it Work? Washington, DC.: National Academy Press, 2002."},{"key":"10.1016\/j.vaccine.2006.07.056_bib15","series-title":"Vaccines","first-page":"887","article-title":"Anthrax Vaccine","author":"Brachman","year":"2004"},{"issue":"1","key":"10.1016\/j.vaccine.2006.07.056_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S0022172400044272","article-title":"Observations on the prophylaxis of experimental pulmonary anthrax in the monkey","volume":"54","author":"Henderson","year":"1956","journal-title":"J Hyg (Lond)"},{"issue":"5","key":"10.1016\/j.vaccine.2006.07.056_bib17","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthrax","volume":"167","author":"Friedlander","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.07.056_bib18","unstructured":"Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2002; 51(45):1024\u20136."},{"issue":"18","key":"10.1016\/j.vaccine.2006.07.056_bib19","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.281.18.1735","article-title":"Anthrax as a biological weapon: medical and public health management","volume":"281","author":"Inglesby","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.vaccine.2006.07.056_bib20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pds.1085","article-title":"An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program","volume":"14","author":"Martin","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.vaccine.2006.07.056_bib21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0264-410X(96)00183-1","article-title":"Adjuvants\u2013a classification and review of their modes of action","volume":"15","author":"Cox","year":"1997","journal-title":"Vaccine"},{"issue":"27\u201328","key":"10.1016\/j.vaccine.2006.07.056_bib22","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.vaccine.2004.03.032","article-title":"Aluminium adjuvants\u2013in retrospect and prospect","volume":"22","author":"Lindblad","year":"2004","journal-title":"Vaccine"},{"issue":"6522","key":"10.1016\/j.vaccine.2006.07.056_bib23","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct B-cell activation","volume":"374","author":"Krieg","year":"1995","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.vaccine.2006.07.056_bib24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I\/II study","volume":"24","author":"Cooper","year":"2004","journal-title":"J Clin Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2006.07.056_bib25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.vaccine.2004.07.014","article-title":"Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response","volume":"23","author":"Siegrist","year":"2004","journal-title":"Vaccine"},{"issue":"19\u201320","key":"10.1016\/j.vaccine.2006.07.056_bib26","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0264-410X(03)00045-8","article-title":"A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant","volume":"21","author":"Halperin","year":"2003","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2006.07.056_bib27","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/01.aids.0000183514.37513.d2","article-title":"CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults","volume":"19","author":"Cooper","year":"2005","journal-title":"AIDS"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2006.07.056_bib28","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1016\/j.vaccine.2004.01.058","article-title":"Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine","volume":"22","author":"Cooper","year":"2004","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2006.07.056_bib29","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.186.10.1623","article-title":"CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity","volume":"186","author":"Chu","year":"1997","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.vaccine.2006.07.056_bib30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nm0897-849","article-title":"Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants","volume":"3","author":"Roman","year":"1997","journal-title":"Nat Med"},{"issue":"21\u201322","key":"10.1016\/j.vaccine.2006.07.056_bib31","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.vaccine.2003.12.020","article-title":"CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques","volume":"22","author":"Klinman","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.07.056_bib32","unstructured":"Update: Investigation of bioterrorism-related anthrax. MMWR Morb Mortal Wkly Rep 2001; 50(45):1008\u201310."},{"issue":"10","key":"10.1016\/j.vaccine.2006.07.056_bib33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3201\/eid0810.020331","article-title":"Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, DC, 2001","volume":"8","author":"Jefferds","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2006.07.056_bib34","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3201\/eid0810.020349","article-title":"Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence","volume":"8","author":"Shepard","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2006.07.056_bib35","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00002371-200411000-00006","article-title":"Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist","volume":"27","author":"Krieg","year":"2004","journal-title":"J Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2006.07.056_bib36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nbt0602-597","article-title":"Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity","volume":"20","author":"Maynard","year":"2002","journal-title":"Nat Biotechnol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06009467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06009467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T06:56:18Z","timestamp":1547448978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06009467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0264410X06009467"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.07.056","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}